Mifepristone Ban Threatens Abortion Access: How Misoprostol Could Become the New Standard

The U.S. Supreme Court is once again at the center of the abortion rights debate after the Fifth Circuit Court of Appeals blocked a Food and Drug Administration (FDA) rule allowing telemedicine prescriptions for mifepristone, one of two drugs in the gold-standard abortion-pill regimen.

On Monday, Supreme Court Justice Samuel Alito issued an order pausing the Fifth Circuit’s ruling until May 11. While abortion advocates welcomed the temporary reprieve, Alito—who authored the 2022 Dobbs decision overturning Roe v. Wade—left the door open for a future ban on mail-order mifepristone. Such a move could drastically reduce access to a drug used by hundreds of thousands of women annually, including in states where abortion is banned.

Nearly two-thirds of abortions in the U.S. now involve medication, with 30% conducted via telemedicine. As opponents intensify their legal attacks on mifepristone, abortion rights advocates are turning to misoprostol, the second drug in the standard regimen, as a potential alternative.

Misoprostol: A Proven Alternative to Mifepristone

Developed in the 1970s to protect the stomach lining, misoprostol also induces uterine contractions, making it effective for medication abortion. While it works best in combination with mifepristone, it is also highly effective on its own.

“In the uterus,” explains Caitlin Gerdts, vice president for research at Ibis Reproductive Health, “what that means is cramping and then expulsion of what’s inside.” Misoprostol is already widely used globally, often available over the counter in countries with restrictive abortion laws. If mifepristone access is curtailed in the U.S., misoprostol-only abortions will likely become far more common.

Misoprostol’s Broader Medical Uses

Beyond abortion, misoprostol has multiple reproductive health applications, including:

• Induction of labor
• Miscarriage management
• Treatment of postpartum hemorrhage

Its versatility and accessibility make it a critical tool in regions with limited healthcare resources.

Legal and Medical Challenges Ahead

Abortion opponents are already responding. In 2024, Louisiana passed a law reclassifying both mifepristone and misoprostol as dangerous controlled substances. Other states are expected to follow suit.

Meanwhile, abortion advocates are preparing for a potential shift to misoprostol-only regimens by:

• Educating patients about side effects, which may be more severe
• Strengthening legal networks and medical hotlines
• Building community support systems to minimize risks
• Convincing clinicians unfamiliar with misoprostol-only protocols

“Despite the fact that very good evidence exists for misoprostol’s effectiveness,” Gerdts notes, “it’s really hard for clinicians to know what to believe or how to interpret it.”

Ongoing Research and Advocacy

To address gaps in medical knowledge, Ibis Reproductive Health has launched the first U.S. clinical trials comparing the two-drug regimen with misoprostol alone. The study aims to provide definitive evidence to guide future abortion protocols.

As the legal battle over mifepristone intensifies, the abortion rights movement is bracing for further restrictions—while preparing to adapt to a changing landscape where misoprostol may play a leading role.